FNIH Biomarkers Consortium NIMBLE Project Receives FDA Nod to Move Forward in Biomarker Qualification
May 15, 2020 — The FNIH Biomarkers Consortium program Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE) has received acceptance from the U.S. Food and Drug Administration (FDA) for its Letter of Intent (LOI). NIMBLE seeks to qualify biomarkers to easily diagnose clinically significant non-alcoholic steatohepatitis, or NASH.
BETHESDA, MD, June 13, 2019 — The Foundation for the National Institutes of Health (FNIH) is proud to announce that President and Executive Director Maria C. Freire, Ph.D., has been named “Executive of the Year” by NonProfit PRO. Each year, the Nonprofit Professionals of the Year Awards celebrate and honor the best and brightest leaders of the not-for-profit sector. Dr. Freire won the “Executive of the Year” Award for leadership of the FNIH over the past six years, which has fueled innovative approaches to biomedical research.
April 23, 2019 - The Foundation for the National Institutes of Health (FNIH) has received top honors again this year from Charity Navigator by earning it’s coveted 4-star rating. Charity Navigator, the nation’s largest independent charity evaluator, has recognized the FNIH with its highest rating for demonstrating strong financial health and commitment to accountability and transparency.
Q&A With David Fryburg, M.D., Principal Consultant, ROI BioPharma Consulting: Building Tools to Improve Diabetes Drug Development
January 25, 2019 — Since 2011, the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium has been shedding new light on diabetes – a disease that affects more than 30 million people in the United States – by examining the function of the beta cell.